US Patent

US9636407 — Caspofungin acetate formulations

Formulation · Assigned to Fresenius Kabi USA LLC · Expires 2032-12-21 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of caspofungin acetate, specifically a solid composition made with caspofungin acetate and at least one amino acid.

USPTO Abstract

A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.

Drugs covered by this patent

Patent Metadata

Patent number
US9636407
Jurisdiction
US
Classification
Formulation
Expires
2032-12-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Fresenius Kabi USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.